Latest News about ARDX
Recent news which mentions ARDX
From Benzinga
Why InMed Pharmaceuticals Shares Tumbled 28%; Here Are 67 Biggest Movers From Friday
November 21, 2022
From Benzinga
From Benzinga
From Motley Fool
Why PaxMedica Shares Are Trading Higher By Over 53%? Here Are 47 Stocks Moving In Friday's Mid-Day Session
November 18, 2022
From Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
November 18, 2022
From Benzinga
Analyst Sees This Kidney Disease Company's Stock Could Rise Sixfold, But Lists Two Issues
November 18, 2022
Tickers
ARDX
From Benzinga
Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday
November 18, 2022
From Benzinga
Hillenbrand, Cisco, Macy's And Other Big Gainers From Thursday
November 18, 2022
From Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
November 17, 2022
From Benzinga
Nasdaq Down 60 Points; Alibaba Posts Upbeat Q2 Earnings
November 17, 2022
From Benzinga
Why Elevate Credit Shares Are Trading Higher By Over 71%? Here Are 43 Stocks Moving In Thursday's Mid-Day Session
November 17, 2022
From Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
November 17, 2022
From Benzinga
S&P 500 Down 1%; Crude Oil Drops Sharply
November 17, 2022
From Benzinga
Why Is CytomX Therapeutics (CTMX) Stock Up 29% Today?
November 17, 2022
From InvestorPlace
Why Is Ardelyx (ARDX) Stock Up 38% Today?
November 17, 2022
From InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022
November 17, 2022
From Benzinga
From Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
November 17, 2022
From Benzinga
From Benzinga
Despite Concerns, FDA Advisory Committee Votes In Favor Of Ardelyx's Kidney Disease Candidate
November 17, 2022
Tickers
ARDX
From Benzinga
Cisco, Bath & Body Works And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
November 17, 2022
From Benzinga
Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
November 14, 2022
From Benzinga
US Stocks Mostly Lower; Nasdaq Drops Over 100 Points
November 14, 2022
From Benzinga
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
November 01, 2022
From Benzinga
From Benzinga